S were identified by searching MEDLINE - Ann Intern Med, 2004 - Am Coll Physicians The introduction of new agents and regimens for the treatment of chronic
hepatitis C, such as pegylated interferons and combination therapy with
ribavirin, has resulted in substantial improvements in sustained virologic ... Cited by 140 - Related articles - All 13 versions
M Buti, A Valdés, F Sánchez-Avila, R Esteban, … - Hepatology(Baltimore, Md.), 2003 - cat.inist.fr Extending combination therapy with peginterferon alfa-2 b plus ribavirin for genotype
1 chronic hepatitis C late responders: A report of 9 cases. ... Cited by 63 - Related articles - All 3 versions
ML Shiffman - Hepatology, 2002 - hawaii.edu Significant advances have been made in the treatment of chronic hepatitis C
virus (HCV) infection during the past 5 years. As a consequence, there is
continuing enthusiasm for retreating patients who did not achieve sustained ... Cited by 81 - Related articles - View as HTML - BL Direct - All 13 versions
L Alric, M Duffaut, J Selves, K Sandre, M … - Journal of hepatology, 2001 - ncbi.nlm.nih.gov BACKGROUND/AIMS: Our aim was to assess whether histological response was
improved by continuing interferon-alpha (IFN) treatment in patients with chronic
hepatitis C (HCV) with a biochemical response and no viral clearance after ... Cited by 54 - Related articles - BL Direct - All 6 versions
- ►sgmjournals.org R Colina, D Casane, S Vasquez, L Garcia- … - Journal of General Virology, 2004 - Soc General Microbiol Hepatitis C virus (HCV) has high genomic variability and, since its discovery,
at least six different types and an increasing number of subtypes have been
reported. Genotype 1 is the most prevalent genotype found in South America. ... Cited by 65 - Related articles - BL Direct - All 5 versions
B Gao, F Hong, S Radaeva - Hepatology, 2004 - hepatitis-central.net Failure of interferon- (IFN- ) treatment in patients with chronic hepatitis C
virus (HCV) infection is a challenging obstacle for clinical and experimental
hepatology. Both viral and host factors have been im- plicated in reducing ... Cited by 66 - Related articles - View as HTML - All 6 versions
- ►ubc.ca [PDF] S Zeuzem, M Diago, E Gane, KR Reddy, P Pockros … - Gastroenterology, 2004 - Elsevier Background & Aims: Patients with chronic hepatitis C and persistently normal
alanine aminotransferase (ALT) levels have been routinely excluded from large
randomized treatment trials; consequently, the efficacy and safety of ... Cited by 133 - Related articles - All 4 versions
S Missiha, J Heathcote, T Arenovich, K Khan, 2007 - nature.com Prior investigation has identified factors associated with response to treatment
in hepatitis C including viral genotype and titre, body weight, hepatic
fibrosis, and adherence to therapy. The lower response rate of ... Cited by 18 - Related articles - BL Direct - All 4 versions
- ►higadocolombia.org [PDF] S Zeuzem, R Hultcrantz, M Bourliere, T Goeser … - Journal of hepatology, 2004 - Elsevier Treatment duration in patients with chronic hepatitis C in the era of standard
interferon-α plus ribavirin was tailored according to hepatitis C virus (HCV)
genotype: patients infected with HCV-1 were treated for 48 weeks, patients ... Cited by 215 - Related articles - All 12 versions
T Berg, C Sarrazin, E Herrmann, H … - Hepatology, 2003 - hawaii.edu In patients with chronic hepatitis C virus (HCV) infection scheduled for a
48-week treatment period, premature discontinuation of treatment was previously
recommended if HCV-RNA levels remained detectable at week 24 of therapy. ... Cited by 137 - Related articles - View as HTML - BL Direct - All 4 versions
